Resveratrol research is nearly twice as intense for diabetic nephropathy (DN) as it is for diabetic retinopathy (DR), according to a bibliometric analysis. While the polyphenol shows preclinical activity across multiple diabetic complications, clinical evidence remains scarce among 182 unique records analyzed between 2016 and 2025.
Nephropathy research intensity leads retinopathy and neuropathy
When the data was restricted solely to preclinical records, the research intensity for both DR and DN was similar.
China drives global resveratrol output
Authors from 43 countries contributed to the analyzed records. Authors from 43 countries contributed.
Annual output rose from 11 unique records in 2016 to a peak of 28 in 2024. Records for diabetic peripheral neuropathy did not appear in the Scopus database until 2020, identifying a gap in early research for nerve-related complications.
SIRT1 and oxidative stress form the thematic core
Keyword mapping revealed that the three complications share a common biological vocabulary centered on SIRT1 and oxidative stress. However, organ-specific markers remain distinct.
| Keyword | Total Occurrences | Primary Domain |
|---|---|---|
| Diabetic Retinopathy | 36 | DR |
| SIRT1 | 22 | Shared (DN/DR) |
Specific terms like “podocyte injury”, “apoptosis”, “inflammation”, and “oxidative stress” stayed with DN, while SIRT1 moved to a separate cluster with autophagy and retinal cells.
Did you know? Resveratrol is often grouped with other polyphenols like curcumin and quercetin. The analysis found that the DPN to DR ratio was significant for quercetin (2.62, 95% CI 1.64 to 4.16) but not for curcumin or resveratrol.
Bioavailability hurdles limit clinical translation
Despite the rise in preclinical publications, the transition to human treatment is stalled by pharmacological limitations. Resveratrol is characterized by very low oral bioavailability, which complicates its use as a systemic treatment for retinal or nerve damage.
The report warns that a publication count is not a count of validated effects and clinicians should not view the volume of preclinical publications as evidence of clinical efficacy.
Which diabetic complications does resveratrol research address?
Which diabetic complication is most studied with resveratrol?
Diabetic nephropathy has the highest research intensity at 0.52% of its total literature.
Why is there so little clinical data on resveratrol for these conditions?
Translation is limited by the compound’s very low oral bioavailability.
When did research into diabetic peripheral neuropathy (DPN) increase?
Scopus records for resveratrol in DPN only began appearing in 2020, suggesting a late start compared to retinopathy and nephropathy research.
The current evidence base remains heavily skewed toward preclinical models, with a small percentage of the analyzed records consisting of clinical studies.